Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report sent to investors on Monday. The firm issued a sell rating on the stock.

Bio-Path Stock Performance

Shares of BPTH stock opened at $0.68 on Monday. The firm has a 50 day moving average price of $0.94 and a two-hundred day moving average price of $1.42. Bio-Path has a 12-month low of $0.61 and a 12-month high of $12.00.

Institutional Investors Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent SEC filing. Hedge funds and other institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.